



DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE

1. Smallpox and Monkeypox Vaccine (Jynneos)

Date of FDA Approval: September 24, 2019

Indication: Prevention of Smallpox and Monkeypox (Orthopoxvirus)

Formulation: Subcutaneous Suspension

Dose: 0.5 mL subcutaneously x 2 doses 4 weeks apart

Mechanism of action: Attenuated, live, nonreplicating Smallpox and Monkeypox Vaccine that elicits humoral and cellular immune responses

2. Semaglutide (Rybelsus)

Date of FDA Approval: September 20, 2019

Indication: Type 2 Diabetes mellitus

Formulation: Tablet

Dose: 3 mg orally once daily for 30 days

Mechanism of action: Glucagon-like Peptide-1 (GLP-1) receptor agonist - reduces blood glucose by stimulating insulin secretion and lowering glucagon secretion, in a glucose-dependent manner.

3. Tenapanor (Ibsrela)

Date of FDA Approval: September 12, 2019

Indication: Irritable Bowel Syndrome with constipation (IBS-C)

Formulation: Tablet

Dose: 50 mg orally twice daily

Mechanism of action: First-in-class, Inhibits Sodium / Hydrogen Exchanger 3 (NHE3), an antiporter on the apical surface of enterocyte of the small intestine and colon primarily responsible for the absorption of dietary sodium

4. Glucagon (Gvoke)

Date of FDA Approval: September 10, 2019

Indication: Severe hypoglycemia in diabetes patients

Formulation: Ready-to-use, auto-injector and pre-filled syringe for subcutaneous injection

Dose:

For adults and pediatric patients aged 12 years and older - 1 mg.

For children aged 2 to < 12 years: < 45 kg - 0.5 mg, ≥ 45 kg - 1 mg

Mechanism of action: Glucagon increases blood glucose concentration by activating hepatic glucagon receptors

References

1. <https://www.drugs.com/newdrugs.html>

2. <https://www.medscape.com/drugs>